Threshold Pharmaceuticals Inc. (NASDAQ: THLD) said late Thursday its third-quarter loss widened on higher research, development, and interest expenses, according to Associated Press.
Best Damn Penny Stocks, a leading financial publication, is pleased to alert investors of stocks on the move. Sign Up for our Free Stock Newsletter
The development-stage biotechnology company lost $6.2 million, or 40 cents per share, compared with a loss of $4.6 million, or 49 cents per share, during the year-ago period.
Threshold reported no revenue, compared with $362,000 a year prior.
Operating expenses rose 4 percent to $5.2 million as the company continued developing its potential cancer treatment TH-302. Meanwhile, interest expense surged to $957,000 from $13,000.
Sign up for the free Best Damn Penny Stocks newsletter. To subscribe, enter your e-mail address into the frame at the bottom of this press release or visit our website
About Best Damn Penny Stocks
Best Damn Penny Stocks is a leading stock web site that allows investors and interested parties to research stocks that are on the move. We also track small cap companies that are on the brink of a financial breakout. To feature a company on our web site please contact us at the email listed below.
Please click here to read the full disclaimer
